الفهرس 
SUBSTANCE USE DISORDEROnly 14 pages are availabe for public view
 |  | from | 174 |  |  |
| | | from | 174 | | |
Abstract
Background: Like the increased clinical use of gabapentin, these trends appear to chronologically align with the opioid overdose crisis and particularly with the increased restrictions on opioid prescription. Among the published literature, the prevalence of gabapentin misuse has been estimated at 1.6% to 6.6% in the general population and 3% to 68% among individuals with a substance use disorder. Gabapentin is well tolerated when consumed at or below the FDA maximum recommended dose of 3600 mg/day.
Objective: the study aims to assess and compare between clinical variables, rate of relapses, Overdose symptoms, pain quality and severity, among patients with OUD only and Opioid with comorbid GUD. Furthermore, this study was conducted to assess clinical correlates in relation to socio-demographics, personality disorders and degree of addiction severity in patient with OUD only and Opioid with comorbid GUD.
Patients and Methods: The study was carried out at Okasha Institute of Psychiatry, Ain Shams University, particularly the outpatient clinic and inpatient unit of addiction medicine. Participants were selected as sample sizes of 30 and 30 according to those meeting, the inclusion Criteria for participants: diagnosed with opioid use disorder/ opioid use disorder with comorbid gabapentin use disorder according to DSM-V, both genders, aged between (18 – 45) years old, Egyptian nationality, and Agreement for written informed consent for participation in this study.
Results: In our study, dose of oral opioid was found to be more than 225mg in 46.7% of the opioid group and less than225 mg in 33.3% of the gabapentin group with an evident statistically high significant difference between both groups and a P-value of 0.004,while heroin sniffing was 76.7% in the opioid group and 33.3% in the gabapentin group with an evident statistically high significant difference between both groups and a P-value of 0.001 and regarding dose of sniffed heroin, it was >1gm in 70% of the opioid group and in 10% of the gabapentin group with an evident statistically high significant difference between both groups and a P-value of 0.000.
Conclusion: The current study showed that patients with opioid with comorbid GUD were associated with higher incidence overdose, history of pain and presence of significant neuropathic pain. The incidence of pain relief as a desirable effect higher in patients with opioid with comorbid GUD compared to patients with OUD. While, the incidence of euphoria as a desirable effect was higher in patients with OUD compared to patients with opioid with comorbid GUD. The patients with OUD have higher incidence of abstinence compared to patients with opioid with comorbid GUD. The patients with OUD have higher doses of oral, Sniffed, and IV opioids compared to patients with opioid with comorbid GUD. OUD patients have more severe medical and psychiatric problems than with comorbid GUD.